KR20140126739A - 루판 트리테르페노이드 유도체 및 이의 약제학적 용도 - Google Patents

루판 트리테르페노이드 유도체 및 이의 약제학적 용도 Download PDF

Info

Publication number
KR20140126739A
KR20140126739A KR1020147025188A KR20147025188A KR20140126739A KR 20140126739 A KR20140126739 A KR 20140126739A KR 1020147025188 A KR1020147025188 A KR 1020147025188A KR 20147025188 A KR20147025188 A KR 20147025188A KR 20140126739 A KR20140126739 A KR 20140126739A
Authority
KR
South Korea
Prior art keywords
compound
independently
mmol
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147025188A
Other languages
English (en)
Korean (ko)
Inventor
펑 루
Original Assignee
장시 칭펑 파마슈티컬 인코포레이티드
펑 차오디
펑 루
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 장시 칭펑 파마슈티컬 인코포레이티드, 펑 차오디, 펑 루 filed Critical 장시 칭펑 파마슈티컬 인코포레이티드
Publication of KR20140126739A publication Critical patent/KR20140126739A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147025188A 2012-02-08 2013-01-30 루판 트리테르페노이드 유도체 및 이의 약제학적 용도 Withdrawn KR20140126739A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210027090.4 2012-02-08
CN201210027090 2012-02-08
CN201310014849.XA CN103242413B (zh) 2012-02-08 2013-01-15 Lupane三萜系衍生物及其药学用途
CN201310014849X 2013-01-15
PCT/CN2013/071100 WO2013117137A1 (en) 2012-02-08 2013-01-30 Lupane triterpenoid derivatives and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
KR20140126739A true KR20140126739A (ko) 2014-10-31

Family

ID=48922317

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147025188A Withdrawn KR20140126739A (ko) 2012-02-08 2013-01-30 루판 트리테르페노이드 유도체 및 이의 약제학적 용도

Country Status (11)

Country Link
US (1) US9428542B2 (cg-RX-API-DMAC7.html)
EP (1) EP2812343B1 (cg-RX-API-DMAC7.html)
JP (1) JP5872074B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140126739A (cg-RX-API-DMAC7.html)
CN (1) CN103242413B (cg-RX-API-DMAC7.html)
AU (1) AU2013218441A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014018953A8 (cg-RX-API-DMAC7.html)
CA (1) CA2860581A1 (cg-RX-API-DMAC7.html)
EA (1) EA201491479A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013117137A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201405819B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
AU2015346303B2 (en) * 2014-11-14 2018-03-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
US9914747B2 (en) 2014-11-14 2018-03-13 VIIV Healthcare UK (No.5) Limited Extended betulinic acid analogs
RU2017118576A (ru) * 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
WO2018029602A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
WO2018029604A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018029610A1 (en) * 2016-08-09 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 n-amide derivatives as hiv inhibitors
WO2018065930A1 (en) * 2016-10-05 2018-04-12 Hetero Labs Limited C-3 triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018069857A1 (en) * 2016-10-12 2018-04-19 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide heterocycle derivatives as hiv inhibitors
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
CN114369134B (zh) * 2020-10-15 2024-12-31 江西青峰药业有限公司 一种Lupane三萜系衍生物葡甲胺盐无定型物及其制备方法和应用
CN114369136A (zh) * 2020-10-15 2022-04-19 江西青峰药业有限公司 一种Lupane三萜系衍生物的碱加成盐及其应用
CN115504947B (zh) * 2022-08-23 2024-04-26 山东和源制药有限公司 一种呋喃酮酸的制备方法
CN116041415B (zh) * 2023-02-01 2023-08-18 吉林农业大学 一种裂环羽扇豆烷衍生物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2009073818A1 (en) * 2007-12-04 2009-06-11 Myriad Genetics, Inc. Compounds and therapeutic use thereof
CA2711424A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
AU2008342536A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel C-21-keto lupane derivatives preparation and use thereof
SG182769A1 (en) 2010-02-11 2012-09-27 Glaxosmithkline Llc Derivatives of betulin
JO3387B1 (ar) * 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين

Also Published As

Publication number Publication date
CN103242413A (zh) 2013-08-14
JP5872074B2 (ja) 2016-03-01
JP2015505545A (ja) 2015-02-23
EP2812343A1 (en) 2014-12-17
US20150011517A1 (en) 2015-01-08
CN103242413B (zh) 2015-08-26
EP2812343B1 (en) 2019-03-13
WO2013117137A1 (en) 2013-08-15
BR112014018953A8 (pt) 2017-07-11
US9428542B2 (en) 2016-08-30
AU2013218441A1 (en) 2014-07-24
CA2860581A1 (en) 2013-08-15
BR112014018953A2 (cg-RX-API-DMAC7.html) 2017-06-20
EP2812343A4 (en) 2015-12-02
EA201491479A1 (ru) 2014-11-28
HK1202553A1 (en) 2015-10-02
ZA201405819B (en) 2015-12-23

Similar Documents

Publication Publication Date Title
CN103242413B (zh) Lupane三萜系衍生物及其药学用途
ES2940263T3 (es) Compuestos químicos
WO2023011513A1 (zh) Shp2抑制剂、包含其的药物组合物及其用途
EP3567035B1 (en) N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer
ES2603262T3 (es) Ácidos aminoindano-carboxílicos y aminotetralin-carboxílicos sustituidos y su uso
WO2021027911A1 (zh) 新型螺环类K-Ras G12C抑制剂
WO2021078301A1 (zh) 蛋白降解剂及其在疾病治疗中的应用
JP6091520B2 (ja) ベツリンのプロペン酸誘導体
CN115867556A (zh) Lpa受体拮抗剂及其用途
JP7687996B2 (ja) スルフィニルアミノベンズアミドおよびスルホニルアミノベンズアミド誘導体
BR112014030284B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CA2834417A1 (en) Novel 3-hydroxyisothiazole 1-oxide derivative
CN109956928B (zh) 吡啶类化合物、其制备方法及用途
WO2023025324A1 (zh) 作为p53调节剂的化合物
CN112824420A (zh) 用作egfr激酶抑制剂的化合物及其应用
WO2023198180A1 (zh) Egfr降解剂
CN107074876B (zh) 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CA3071992A1 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
TWI910729B (zh) 塞浦西他啶衍生物
CA3099051C (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
CN118076592A (zh) Shp2抑制剂、包含其的药物组合物及其用途
HK40049106A (en) Sulfonylaminobenzamide derivatives
HK40049106B (en) Sulfonylaminobenzamide derivatives
HK1202553B (en) Lupane triterpenoid derivatives and pharmaceutical use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140905

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid